Daniel Tasse - 29 May 2026 Form 4 Insider Report for REGENXBIO Inc. (RGNX)

Reporting relationship: Director
Issuer ticker: RGNX
Reported as of: 29 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jun 2026, 17:21:14 UTC
Prior SEC filing: 24 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Patrick J. Christmas as attorney-in-fact

Key filing fact

Daniel Tasse filed Form 4 for REGENXBIO Inc. (RGNX) on 02 Jun 2026.

Key facts

This page summarizes Daniel Tasse's Form 4 filing for REGENXBIO Inc. (RGNX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Jun 2026, 17:21.

Change

Previous filing in this sequence was filed on 24 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001502785 Primary reporting owner

Tasse Daniel

Relationship: Director
Address: C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE
Signature: /s/ Patrick J. Christmas as attorney-in-fact
Signature date: 02 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RGNX transaction

Common Stock

Award

Transaction value
Shares: +9,807
Change %: +51%
Price: $0.000000^*
Shares after: 28,861
Date: 29 May 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RGNX transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value
Shares: +46,600
Change %
Price: $0.000000^*
Shares after: 46,600
Date: 29 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 46,600
Exercise price: $7.01
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer.

Footnote F2

The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer.